Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Abbott Laboratories

Expert Ratings for Abbott Laboratories

Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings within the last quarter:

Benzinga

Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook

Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion. Worldwide sales, excluding…

Benzinga

Abbott Laboratories: Q1 Earnings Insights

Abbott Laboratories (NYSE:ABT) reported its Q1 earnings results on Wednesday, April 20, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

If You Invested $1000 In Abbott Laboratories 5 Years Ago, Here's How Much You Would Have Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 8.67% on an annualized basis producing an average annual return of 21.94%. Currently, Abbott Laboratories has a market capitalization of $209.78 billion.

Benzinga

Earnings Preview: Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2022-04-20. Here's what investors need to know before the announcement. Analysts estimate that Abbott Laboratories will report an earnings per share (EPS) of $1.47.

Benzinga

Abbott Laboratories vs. Zimmer Biomet Holdings: Which Medical Device Stock is a Better Buy?

The medical devices industry is thriving and the integration of advanced technologies position the industry well for growth. Therefore, prominent players in this space, Abbott Laboratories (ABT) and Zimmer Biomet Holdings (ZBH), should benefit. But which of these stocks is a better buy now? Read more to find out.

StockNews.com

Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns. On the macro, investor attention seems to be focused less on revenue growth and more…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Looking Into Abbott Laboratories's Recent Short Interest

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 28.81% since its last report. The company recently reported that it has 13.33 million shares sold short, which is 0.76% of all regular shares that are available for trading.

Benzinga

Eton Pharmaceuticals Names James Gruber Finance Chief

Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through May to ensure a smooth transition. Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw…

Benzinga

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

StockNews.com

DeJoy may have new conflict of interest

Justice Department urged to investigate after watchdog group found DeJoy owns stock in Abbott Laboratories

Salon

Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.51% on an annualized basis producing an average annual return of 15.1%. Currently, Abbott Laboratories has a market capitalization of $211.63 billion.

Benzinga

Abbott Laboratories Whale Trades For March 29

A whale with a lot of money to spend has taken a noticeably bearish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories (NYSE:ABT) we detected 11 strange trades.

Benzinga

FDA Inspection Flags Quality Control Issues At Abbott's Michigan Facility

An inspection at the Abbott Laboratories (NYSE: ABT) facility in Sturgis, Michigan,

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyzing Abbott Laboratories's Short Interest

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 15.69% since its last report. The company recently reported that it has 10.37 million shares sold short, which is 0.59% of all regular shares that are available for trading.

Benzinga

A Bearish Sign Appears On Abbott Laboratories's Chart

If history is any guide, there may be trouble ahead for shares of Abbott Laboratories (NYSE:ABT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

CNBC's Final Trades: Interactive Brokers, Abbott Laboratories, Apple And This REIT Stock

On CNBC’s “Halftime Report Final Trades,” Joseph Terranova of Virtus Investment Partners chose Interactive Brokers Group, Inc. (NASDAQ: IBKR) as his top pick.

Benzinga

Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 3.32% on an annualized basis.

Get all your
news in one place.

100’s of premium titles.
One news app.

Chicago Tribune

Abbott facing lawsuits, FDA investigation over recalled infant formula after reports of illness, death

Parents who bought recalled infant formulas made by Abbott Laboratories are filing proposed class-action lawsuits against Abbott, as the U.S. Food and Drug Administration investigates reports of three babies who became sick and two who died after consuming the formulas.

Benzinga

Abbott Recalls Baby Formula Manufactured At Michigan facility

Abbott Laboratories (NYSE: ABT) recalls powdered baby formulas, including Similac, made at a Michigan facility after

StockNews.com

3 Diabetes Stocks That are Better Investments Than Senseonics

Despite the ongoing global public health crisis, fundamentally-sound companies focused on diabetic treatments are seemingly unfazed. So, given Senseonics' (SENS) relative overvaluation and bleak growth prospects, we think it could be wise to bet on diabetes stocks Novo Nordisk (NVO), Eli Lilly (LLY), and Abbott Laboratories (ABT). Let’s discuss.

Benzinga

What 5 Analyst Ratings Have To Say About Abbott Laboratories

Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Chicago Tribune

Abbott sold $2.1 billion worth of rapid COVID-19 tests in the last three months of 2021

As people across the country continue to grab at-home, COVID-19 tests off store shelves, Abbott Laboratories — the maker of one of the most popular of those tests — reported a stellar fourth quarter and financial year.

Benzinga

Abbott Laboratories Whale Trades For January 26

Someone with a lot of money to spend has taken a bullish stance on Abbott Laboratories (NYSE:ABT). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Abbott Posts $2.3B In COVID-19 Test Sales In Q4; Issues FY22 Outlook

Abbott Laboratories (NYSE: ABT) has reported

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.